208 related articles for article (PubMed ID: 26651282)
1. Salvage rates after progression of high-risk neuroblastoma with a soft tissue mass.
Murphy JM; Lim II; Farber BA; Heaton TE; Basu EM; Roberts SS; Modak S; Kushner BH; LaQuaglia MP
J Pediatr Surg; 2016 Feb; 51(2):285-8. PubMed ID: 26651282
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma.
Basta NO; Halliday GC; Makin G; Birch J; Feltbower R; Bown N; Elliott M; Moreno L; Barone G; Pearson AD; James PW; Tweddle DA; McNally RJ
Br J Cancer; 2016 Oct; 115(9):1048-1057. PubMed ID: 27701387
[TBL] [Abstract][Full Text] [Related]
3. [Long-term follow-up of neuroblastoma in children less than 18 months of age].
Zhao J; Pan C; Xu M; Zhou M; Gao YJ; Hu WT; Tang JY
Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):754-759. PubMed ID: 29050113
[No Abstract] [Full Text] [Related]
4. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
5. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children].
Fan HJ; Huang C; Su Y; Wang XD; Zhou YC; Duan C; Zhao W; Zhao Q; Jin M; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):863-869. PubMed ID: 31665841
[No Abstract] [Full Text] [Related]
7. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.
Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH
Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634
[TBL] [Abstract][Full Text] [Related]
8. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.
Garaventa A; Parodi S; De Bernardi B; Dau D; Manzitti C; Conte M; Casale F; Viscardi E; Bianchi M; D'Angelo P; Zanazzo GA; Luksch R; Favre C; Tamburini A; Haupt R
Eur J Cancer; 2009 Nov; 45(16):2835-42. PubMed ID: 19616426
[TBL] [Abstract][Full Text] [Related]
9. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
Schmidt ML; Lukens JN; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Perez C; Haase GM; Matthay KK
J Clin Oncol; 2000 Mar; 18(6):1260-8. PubMed ID: 10715296
[TBL] [Abstract][Full Text] [Related]
10. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
12. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease.
Simon T; Hero B; Bongartz R; Schmidt M; Müller RP; Berthold F
Strahlenther Onkol; 2006 Jul; 182(7):389-94. PubMed ID: 16826357
[TBL] [Abstract][Full Text] [Related]
13. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
[No Abstract] [Full Text] [Related]
14. Late relapse and prognosis for neuroblastoma patients surviving 5 years or more: a report from the European Neuroblastoma Study Group "Survey".
Cotterill SJ; Pearson AD; Pritchard J; Kohler JA; Foot AB;
Med Pediatr Oncol; 2001 Jan; 36(1):235-8. PubMed ID: 11464893
[TBL] [Abstract][Full Text] [Related]
15. Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.
Cai J; Pan C; Tang Y; Chen J; Zhou M; Li B; Xue H; Shen S; Gao Y; Zhang A; Tang J
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1327-1335. PubMed ID: 28283783
[TBL] [Abstract][Full Text] [Related]
16. Management and outcome of stage 3 neuroblastoma.
Modak S; Kushner BH; LaQuaglia MP; Kramer K; Cheung NK
Eur J Cancer; 2009 Jan; 45(1):90-8. PubMed ID: 18996003
[TBL] [Abstract][Full Text] [Related]
17. [Occurrence and prognostic impact of selected factors in neuroblastoma in children].
Wieczorek A; Balwierz W
Przegl Lek; 2010; 67(6):393-8. PubMed ID: 21344768
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
[TBL] [Abstract][Full Text] [Related]
19. Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma.
Cheung NK; Guo HF; Heller G; Cheung IY
Clin Cancer Res; 2000 Jul; 6(7):2653-60. PubMed ID: 10914706
[TBL] [Abstract][Full Text] [Related]
20. Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma.
Ashraf K; Shaikh F; Gibson P; Baruchel S; Irwin MS
Pediatr Blood Cancer; 2013 Oct; 60(10):1636-41. PubMed ID: 23650219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
